This inventor holds 2 USPTO granted patents and 3 EPO patents. Top assignee: Ratiopharm Gmbh. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mumbai, IN (2014)
- Maharashtra, IN (2015)
Company Filing History:
Years Active: 2014-2015
Title: Channaveerayya Hiremath: Innovator in Pharmaceutical Chemistry
Introduction
Channaveerayya Hiremath is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug formulations. With a total of 2 patents, his work has the potential to impact the treatment of various medical conditions.
Latest Patents
Channaveerayya's latest patents include advancements in the formulation of Afatinib. His first patent describes the salts and polymorphic forms of Afatinib, detailing the processes for their preparation. This invention also encompasses pharmaceutical compositions of Afatinib salts and crystalline forms, along with methods for their preparation and application in treating patients. His second patent focuses on a process for producing pharmaceutically acceptable salts of fingolimod. This involves reacting a specific acylamide with an acidic compound, resulting in various acceptable salts and a polymorphic form of fingolimod hydrochloride.
Career Highlights
Channaveerayya is currently associated with Ratiopharm GmbH, where he continues to innovate in the pharmaceutical sector. His expertise in drug formulation and development has positioned him as a valuable asset in his field.
Collaborations
Channaveerayya has collaborated with several professionals, including Ramesh Matioram Gidwani and Manoj Dalsingar Yadav. These collaborations have further enhanced his research and development efforts.
Conclusion
Channaveerayya Hiremath's contributions to pharmaceutical chemistry through his patents demonstrate his commitment to advancing medical treatments. His innovative work continues to pave the way for new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
